INS and Hypoglycemia: Insulin lispro and Insulin aspart are the two major rapid-acting insulin analogs that emerged in the late 80s and 90s, each demonstrating an ability to reduce glycosylated hemoglobin levels and the frequency of hypoglycemia in patients [67].